• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Lessons from the ACDC-RP trial: Clinical trial design for radical prostatectomy neoadjuvant therapy trials.

作者信息

Sayyid Rashid K, Fleshner Neil E

出版信息

Oncotarget. 2024 Sep 30;15:660-661. doi: 10.18632/oncotarget.28648.

DOI:10.18632/oncotarget.28648
PMID:39347713
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11441411/
Abstract
摘要

相似文献

1
Lessons from the ACDC-RP trial: Clinical trial design for radical prostatectomy neoadjuvant therapy trials.ACDC-RP 试验的经验教训：根治性前列腺切除术新辅助治疗试验的临床试验设计
Oncotarget. 2024 Sep 30;15:660-661. doi: 10.18632/oncotarget.28648.
2
Letter: A Prospective Randomized Trial of Neoadjuvant Chemohormonal Therapy vs Hormonal Therapy in Locally Advanced Prostate Cancer Treated by Radical Prostatectomy.信函：新辅助化学激素疗法与激素疗法在接受根治性前列腺切除术的局部晚期前列腺癌治疗中的前瞻性随机试验
J Urol. 2024 Oct;212(4):626-627. doi: 10.1097/JU.0000000000004127. Epub 2024 Jul 8.
3
Chemotherapy and novel therapeutics before radical prostatectomy for high-risk clinically localized prostate cancer.高危临床局限性前列腺癌根治性前列腺切除术前行化疗及新型治疗方法
Urol Oncol. 2015 May;33(5):217-25. doi: 10.1016/j.urolonc.2014.11.020. Epub 2015 Jan 14.
4
Cancer and Leukemia Group B (CALGB) 90203: a randomized phase 3 study of radical prostatectomy alone versus estramustine and docetaxel before radical prostatectomy for patients with high-risk localized disease.癌症与白血病B组（CALGB）90203研究：一项针对高危局限性疾病患者的随机3期研究，比较单纯根治性前列腺切除术与根治性前列腺切除术前行雌莫司汀和多西他赛治疗的疗效。
Urology. 2003 Dec 29;62 Suppl 1:55-62. doi: 10.1016/j.urology.2003.09.052.
5
ARNEO: A Randomized Phase II Trial of Neoadjuvant Degarelix with or Without Apalutamide Prior to Radical Prostatectomy for High-risk Prostate Cancer.ARNEO：新辅助去势治疗联合或不联合阿帕鲁胺用于高危前列腺癌根治术前的随机 II 期临床试验。
Eur Urol. 2023 Jun;83(6):508-518. doi: 10.1016/j.eururo.2022.09.009. Epub 2022 Sep 24.
6
Biological effect of neoadjuvant androgen-deprivation therapy assessed on specimens from radical prostatectomy: a systematic review.基于根治性前列腺切除术标本评估新辅助雄激素剥夺治疗的生物学效应：一项系统综述
Minerva Urol Nefrol. 2018 Aug;70(4):370-379. doi: 10.23736/S0393-2249.18.03022-9. Epub 2018 Feb 1.
7
Post prostatectomy outcomes of patients with high-risk prostate cancer treated with neoadjuvant androgen blockade.接受新辅助雄激素阻断治疗的高危前列腺癌患者前列腺切除术后的结局。
Prostate Cancer Prostatic Dis. 2018 Sep;21(3):364-372. doi: 10.1038/s41391-017-0009-6. Epub 2017 Dec 20.
8
Neoadjuvant Approaches Prior To Radical Prostatectomy.根治性前列腺切除术之前的新辅助方法。
Cancer J. 2020 Jan/Feb;26(1):2-12. doi: 10.1097/PPO.0000000000000424.
9
Neoadjuvant degarelix with or without apalutamide followed by radical prostatectomy for intermediate and high-risk prostate cancer: ARNEO, a randomized, double blind, placebo-controlled trial.新辅助去势治疗联合或不联合阿帕鲁胺治疗中高危前列腺癌行根治性前列腺切除术：ARNEO，一项随机、双盲、安慰剂对照试验。
BMC Cancer. 2018 Apr 2;18(1):354. doi: 10.1186/s12885-018-4275-z.
10
[Radical prostatectomy with neoadjuvant hormone therapy for cT3 prostate cancer].[新辅助激素治疗联合根治性前列腺切除术治疗cT3期前列腺癌]
Nihon Rinsho. 2005 Feb;63(2):271-8.

本文引用的文献

1
Treatment patterns and outcomes in metastatic castration-resistant prostate cancer patients with and without somatic or germline alterations in homologous recombination repair genes.同源重组修复基因存在或不存在体细胞或种系改变的转移性去势抵抗性前列腺癌患者的治疗模式及预后
Ann Oncol. 2024 May;35(5):458-472. doi: 10.1016/j.annonc.2024.01.011. Epub 2024 Feb 27.
2
Neoadjuvant Cabazitaxel plus Abiraterone/Leuprolide Acetate in Patients with High-Risk Prostate Cancer: ACDC-RP Phase II Trial.新辅助卡巴他赛加阿比特龙/亮丙瑞林在高危前列腺癌患者中的应用：ACDC-RP Ⅱ期试验。
Clin Cancer Res. 2023 Oct 2;29(19):3867-3874. doi: 10.1158/1078-0432.CCR-23-0731.
3
ARNEO: A Randomized Phase II Trial of Neoadjuvant Degarelix with or Without Apalutamide Prior to Radical Prostatectomy for High-risk Prostate Cancer.ARNEO：新辅助去势治疗联合或不联合阿帕鲁胺用于高危前列腺癌根治术前的随机 II 期临床试验。
Eur Urol. 2023 Jun;83(6):508-518. doi: 10.1016/j.eururo.2022.09.009. Epub 2022 Sep 24.
4
Neoadjuvant hormonal therapy before radical prostatectomy in high-risk prostate cancer.高危前列腺癌根治性前列腺切除术前行新辅助激素治疗。
Nat Rev Urol. 2021 Dec;18(12):739-762. doi: 10.1038/s41585-021-00514-9. Epub 2021 Sep 15.
5
Inherited DNA-Repair Gene Mutations in Men with Metastatic Prostate Cancer.转移性前列腺癌男性患者的遗传性DNA修复基因突变
N Engl J Med. 2016 Aug 4;375(5):443-53. doi: 10.1056/NEJMoa1603144. Epub 2016 Jul 6.
6
Intense androgen-deprivation therapy with abiraterone acetate plus leuprolide acetate in patients with localized high-risk prostate cancer: results of a randomized phase II neoadjuvant study.醋酸阿比特龙联合醋酸亮丙瑞林对局限性高危前列腺癌患者进行强化雄激素剥夺治疗：一项随机II期新辅助研究的结果
J Clin Oncol. 2014 Nov 20;32(33):3705-15. doi: 10.1200/JCO.2013.53.4578. Epub 2014 Oct 13.
7
Neo-adjuvant and adjuvant hormone therapy for localised and locally advanced prostate cancer.局限性和局部晚期前列腺癌的新辅助和辅助激素治疗
Cochrane Database Syst Rev. 2006 Oct 18;2006(4):CD006019. doi: 10.1002/14651858.CD006019.pub2.
8
Neoadjuvant Therapy for Prostate Cancer: An Oncologist's Perspective.前列腺癌的新辅助治疗：肿瘤学家的观点
Rev Urol. 2003;5 Suppl 3(Suppl 3):S28-37.
9
Randomized comparative study of 3 versus 8-month neoadjuvant hormonal therapy before radical prostatectomy: biochemical and pathological effects.前列腺癌根治术前3个月与8个月新辅助激素治疗的随机对照研究：生化和病理效应
J Urol. 2001 Aug;166(2):500-6; discussion 506-7.
10
CUOG randomized trial of neoadjuvant androgen ablation before radical prostatectomy: 36-month post-treatment PSA results. Canadian Urologic Oncology Group.根治性前列腺切除术前行新辅助雄激素剥夺治疗的CUOG随机试验：治疗后36个月的前列腺特异性抗原结果。加拿大泌尿外科肿瘤学组
Urology. 1999 Apr;53(4):757-63. doi: 10.1016/s0090-4295(98)00616-5.